By the Top Tier Newswire AI Desk · September 30, 2026 at 11:21 AM ET · reviewed against 24 wire stories
SUMMIT THERAPEUTICS (SMMT) is up +7.44% in the latest session. Our newswire has captured 24 stories on SMMT across 14 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why SMMT stock is up today
SUMMIT THERAPEUTICS shares rose 7.44 percent to $17.61 on Tuesday, driven by a major $2 billion investment from AstraZeneca. The deal involves AstraZeneca acquiring convertible preferred shares in Summit Therapeutics, which implies a $18.36 common-stock conversion price based on a five-day volume-weighted average price plus 10 percent. The investment is intended to accelerate the development of ivonescimab, a first-in-class bispecific antibody.
What Happened
The stock opened at $16.44 and reached an intraday high of $17.66 at 11:10 AM ET. The session saw a low of $16.17 at 9:35 AM ET. The price increase followed the announcement of the strategic equity investment by AstraZeneca, which has entered into a clinical collaboration agreement with Summit Therapeutics to evaluate sonesitatug vedotin in combination with ivonescimab. The investment marks a significant vote of confidence in Summit's development pipeline and strengthens its balance sheet.
H.C. Wainwright and Citizens reissued their Neutral stock ratings for Summit Therapeutics following the AstraZeneca deal. Citigroup maintained its Buy rating and raised its price target to $43. The stock is currently trading below the implied conversion price of the AstraZeneca investment, which is seen as a potential catalyst for further gains.
What The Data Shows
The stock traded on 4.0 million shares, which is 0.7 times the 3-month daily average. The session saw two notable options prints, with put premium at $1.9 million and the largest single print at $1.1 million. Over the last eight sessions, the stock declined 3.8 percent from $17.95 to $17.26. On September 30, the stock printed 20 fresh 52-week highs and 8 fresh 52-week lows. The stock currently trades within its 52-week range of $12.07 to $29.23.
What To Watch
Investors will be watching the progress of clinical trials for ivonescimab and the outcomes expected in 2026. These milestones will be critical in determining the long-term value of the investment and the stock's trajectory.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SMMT · today's session (5-min) · +3.95% vs prior close · updated 3:57 PM ETAI sentiment, last 36h · averaged over 24 stories · 61/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
4h ago24/7 Wall St.BULLISH 63M&A
AstraZeneca’s $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical deadlines in 2026 will determine whether Wall Street or the pharma giant read ivonescimab correctly.
Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal
Citizens reiterates Summit Therapeutics stock rating after AstraZeneca deal
1d agoSeeking AlphaBULLISH 58General
Summit Therapeutics: Stronger Balance Sheet Helps, But It Does Not De-Risk Ivonescimab
Summit Therapeutics secured a $2B strategic investment from AstraZeneca and enabling further clinical development of ivonescimab. Read more on SMMT stock here.
1d agoMarketChameleonBULLISH 63M&A
AstraZeneca’s $2 Billion Preferred-Share Deal Puts an $18.36 Conversion Price on Summit Therapeutics (SMMT)
Summit Therapeutics said AstraZeneca will invest $2.0 billion in convertible preferred shares, implying an $18.36 common-stock conversion price based on a five-day VWAP plus 10%. The companies also outlined a clinical collaboration to study ivonescimab with AstraZeneca’s sonesitatug vedotin (sone-ve) in gastrointestinal cancers and described a non-binding plan to explore additional combinations with AstraZeneca oncology medicines, including ADCs.
1d agoInvestors.comBULLISH 73M&A
AstraZeneca Pays $2 Bil To Get Into High-Profile Cancer Space
Summit Therapeutics stock catapulted Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.
1d agoThe FlyBULLISH 67General
Morning Movers: Summit Therapeutics jumps after AstraZeneca investment
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →